NCT07042295View on ClinicalTrials.gov

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 22, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Locally Recurrent Skin Squamous Cell CarcinomaMetastatic Skin Squamous Cell Carcinoma
Interventions
DRUG

Amivantamab and Recombinant Human Hyaluronidase

Given SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

BIOLOGICAL

Cetuximab

Given IV

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH